mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-2-131-137mrj-1017Research ArticleОБЗОРЫREVIEWSБиологически активные добавки в XXI веке: неденатурированный коллаген II типа как пример препарата для надлежащей медицинской практикиBiologically active additives in the 21st century: undenatured type II collagen as an example of good medical practiceДыдыкинаИ. С.DydykinaI. S.

Ирина Степановна Дыдыкина

115522, Москва, Каширское шоссе, 34А

Irina Stepanovna Dydykina

34A, Kashirskoe Shosse, Moscow 115522

dydykina_is@mail.ruДибровД. А.DibrovD. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

НурбаеваК. С.NurbaevaK. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

КоваленкоП. С.KovalenkoP. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

КоваленкоА. А.KovalenkoA. A.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St. Build. 2, Moscow 119991

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation202030052020142131137Copyright © Дыдыкина И.С., Дибров Д.А., Нурбаева К.С., Коваленко П.С., Коваленко А.А., 20202020Дыдыкина И.С., Дибров Д.А., Нурбаева К.С., Коваленко П.С., Коваленко А.А.Dydykina I.S., Dibrov D.A., Nurbaeva K.S., Kovalenko P.S., Kovalenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1017

В статье рассмотрены современные сведения о биологически активных добавках (БАД), подчеркнута их роль в нормализации и/или улучшении функционального состояния органов и систем, в том числе микрофлоры желудочно-кишечного тракта, снижении риска заболеваний и др. Представлены данные о потреблении и оборотах БАД, определения и классификации этой группы веществ, основные документы, регламентирующие контроль их производства и продвижения в разных странах и в России. В качестве примера БАД, соответствующего правилам надлежащей медицинской практики, рассмотрен неденатурированный коллаген II типа, который вырабатывается из хряща грудины цыплят (UC-II® ) и входит в состав препарата Сустафлекс. Терапевтические свойства неденатурированного коллагена II типа подтверждены клиническими испытаниями. Описаны механизм его действия, доказательства эффективности и безопасности, возможность использования для профилактики и комплексной терапии остеоартрита (ОА) коленных суставов, а также в качестве альтернативного средства лечения ОА.

The paper deals with an update on biologically active additives (BAAs) and emphasizes their role in normalizing and/or improving the functional status of organs and systems, including the gastrointestinal tract microflora, in reducing the risk of diseases, etc. It gives data on the consumption and turnover of BAAs, definitions and classifications of this group of substances, the basic documents governing the control of their production and promotion in different countries and in Russia. Undenatured type II collagen (UC-II® ) that is made from the chicken sternal cartilage and is a component of Sustaflex is considered as an example of the BAA that is compliant with good medical practice regulations. The therapeutic properties of UC-II® have been confirmed in clinical trials. The paper describes the mechanism of action of the BAA, evidence for its efficacy and safety, and the possibility of its administration for the prevention and combination treatment of knee osteoarthritis (OA) and its use as an alternative treatment for OA.

биологически активные добавкиболезни костно-мышечной системыостеоартрит коленных суставовмеханизм оральной толерантностинеденатурированный коллаген II типа (UC-II®)biologically active additivesmusculoskeletal system diseasesknee osteoarthritismechanism of oral toleranceundenatured type II collagen (UC-II®)Статья спонсируется компанией «ФП «Оболенское» (OBL Pharm). Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также принятии решения о представлении статьи для публикации.The paper has been sponsored by the pharmaceutical enterprise «Obolenskoe» (OBL Pharm). The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.ReferencesПетренко АС, Пономарева МН, Суханов БП и др. Законодательное регулирование обращения биологически активных добавок к пище в Европейском союзе и отдельных странах Европы. Часть 1. Вопросы питания. 2014;(3):32-8.Petrenko AS, Ponomareva MN, Sukhanov BP, et al. Legal regulation of the circulation of biologically active food additives in the European Union and certain European countries. Part 1. Voprosy pitaniya. 2014;(3):32-8. (In Russ.).Manson J, Bassuk S. Vitamin and mineral supplements what clinicians need to know. JAMA. 2018 Mar 6;319(9):859-60. doi: 10.1001/jama.2017.21012Manson J, Bassuk S. Vitamin and mineral supplements what clinicians need to know. JAMA. 2018 Mar 6;319(9):859-60. doi: 10.1001/jama.2017.21012ЗАО «Группа ДСМ». Фармацевтический рынок России. Итоги 2018 года: аналитический отчет. 2018. Available from: https://www.dsm.ru/marketing/free-information/analytic-reports/JSC «DSM Group». Russian pharmaceutical market. Results of 2018: analytical report. 2018. Available from: https://www.dsm.ru/marketing/free-information/analytic-reports/Позняковский ВМ, Суханов БП. Биологически активные добавки в современной нутрициологии. Техника и технология пищевых производств. 2009;(2): 44-9.Poznyakovskii VM, Sukhanov BP. Biologically active additives in the modern nutrition. Tekhnika i tekhnologiya pishchevykh proizvodstv. 2009;(2):44-9. (In Russ.).Тутельян ВА, Аксюк ИН, Батурин АК. Пищевые продукты и пищевые добавки. Определение безопасности и эффективности биологически активных добавок к пище. Методические указания. 1999.Tutel'yan VA, Aksyuk IN, Baturin AK. Pishchevye produkty i pishchevye dobavki. Opredelenie bezopasnosti i effektivnosti biologicheski aktivnykh dobavok k pishche. Metodicheskie ukazaniya [Food and nutritional supplements. Determining the safety and effectiveness of dietary supplements. Methodical instructions]. 1999.European Parliament and the Council of the European Union. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Official Journal of the European Union. 2002;(183):51-7.European Parliament and the Council of the European Union. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Official Journal of the European Union. 2002;(183):51-7.Вышковский ГЛ. Энциклопедия лекарств 2020 регистра лекарственных средств России. Москва: ВЕДАНТА; 2019.Vyshkovskii GL. Entsiklopediya lekarstv 2020 registra lekarstvennykh sredstv Rossii [Encyclopedia of medicines 2020 of the Russian register of medicines]. Moscow: VEDANTA; 2019.СанПиН 2.3.2.1078–01 «Гигиенические требования безопасности и пищевой ценности пищевых продуктов». 2001.Sanitary rules and regulations 2.3.2.1078–01 «Hygienic requirements for food safety and nutritional value». 2001.Гаммель ИВ, Суворова ОВ, Запорожская ЛИ. Современные аспекты классификации и регулирования оборота биологически активных добавок к пище. Медицинский альманах. 2017;46(1):94-8.Gammel' IV, Suvorova OV, Zaporozhskaya LI. Modern aspects of classification and regulation of turnover of biologically active food additives. Meditsinskii al'manakh. 2017; 46(1):94-8. (In Russ.).Lynch SV, Siew C, Shanahan F, et al. Translating the gut microbiome: ready for the clinic? Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):656-661. doi: 10.1038/s41575-019-0204-0. Epub 2019 Sep 27.Lynch SV, Siew C, Shanahan F, et al. Translating the gut microbiome: ready for the clinic? Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):656-661. doi: 10.1038/s41575-019-0204-0. Epub 2019 Sep 27.Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and Research Resources. Nutrients. 2018 Jan 4; 10(1). pii: E41. doi: 10.3390/nu10010041Dwyer JT, Coates PM, Smith MJ. Dietary Supplements: Regulatory Challenges and Research Resources. Nutrients. 2018 Jan 4; 10(1). pii: E41. doi: 10.3390/nu10010041Codex Alimentarius Comission. Codex Alimentarius Comission Guidelines for Use of Nutrition and Health Claims CAC/GL 23. 1997.Codex Alimentarius Comission. Codex Alimentarius Comission Guidelines for Use of Nutrition and Health Claims CAC/GL 23. 1997.The European Parliament and the Council of the European Union. Regulation (EC) № 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union. 2007;(12):3-18.The European Parliament and the Council of the European Union. Regulation (EC) № 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union. 2007;(12):3-18.The European Parliament and the Council of the European Union. Comission Regulation (EU) № 1048/2012 of 8 November 2012 on the authorisation of a health claim made on foods and referring to the reduction of disease risk. Official Journal of the European Union. 2012;(310):38-40.The European Parliament and the Council of the European Union. Comission Regulation (EU) № 1048/2012 of 8 November 2012 on the authorisation of a health claim made on foods and referring to the reduction of disease risk. Official Journal of the European Union. 2012;(310):38-40.Петренко АС, Пономарева МН, Суханов БП и др. Законодательное регулирование обращения биологически активных добавок к пище в Европейском союзе и отдельных странах Европы. Часть 2. Вопросы питания. 2014;83(4):52-7.Petrenko AS, Ponomareva MN, Sukhanov BP, et al. Legal regulation of the circulation of biologically active food additives in the European Union and certain European countries. Part 2. Voprosy pitaniya. 2014;83(4): 52-7. (In Russ.).Tucker J, Fischer T, Upjohn L, et al. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA Netw Open. 2018 Oct 5; 1(6):e183337. doi: 10.1001/jamanetworkopen.2018.3337Tucker J, Fischer T, Upjohn L, et al. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA Netw Open. 2018 Oct 5; 1(6):e183337. doi: 10.1001/jamanetworkopen.2018.3337Bruyere O, Cooper C, Pelletier J, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.Bruyere O, Cooper C, Pelletier J, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.Денисов ЛН, Цветкова ЕС, Голубев ГШ и др. Алгоритм лечения остеоартрита коленного сустава европейского общества по клиническим и экономическим аспектам остеопороза и остеоартрита (ESCEO). Применим в Российской клинической практике: совместное заключение ведущих российских специалистов и экспертов (ESCEO) по остеоартриту. Научнопрактическая ревматология. 2016;54(6): 641-53. doi: 10.14412/1995-4484-2016-641-653Denisov LN, Tsvetkova ES, Golubev GSh, et al. Algoritm The European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis is applicable to russian clinical practice: a consensus statement of leading russian and ESCEO osteoarthritis experts. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(6):641-53. (In Russ.). doi: 10.14412/1995-4484-2016-641-653Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec; 49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec; 49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb; 72(2):149-62. doi: 10.1002/acr.24131. Epub 2020 Jan 6.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb; 72(2):149-62. doi: 10.1002/acr.24131. Epub 2020 Jan 6.Committee on toxicity of chemicals in food, consumer products and the environment. COT statement 2009/01. http://cot.food.gov.uk/pdfs/cotstatementgluco200901.pdfCommittee on toxicity of chemicals in food, consumer products and the environment. COT statement 2009/01. http://cot.food.gov.uk/pdfs/cotstatementgluco200901.pdfSchauss AG, Merkel DJ, Glaza SM, Sorenson SR. Acute and subchronic oral toxicity studies in rats of a hydrolyzed chicken sternal cartilage preparation. Food Chem Toxicol. 2007 Feb;45(2):315-21. Epub 2006 Aug 30. doi: 10.1016/j.fct.2006.08.011Schauss AG, Merkel DJ, Glaza SM, Sorenson SR. Acute and subchronic oral toxicity studies in rats of a hydrolyzed chicken sternal cartilage preparation. Food Chem Toxicol. 2007 Feb;45(2):315-21. Epub 2006 Aug 30. doi: 10.1016/j.fct.2006.08.011Xin W, Heilig J, Paulsson M, Zaucke F. Collagen II regulates chondroycte integrin expression profile and differentiation. Connect Tissue Res. 2015;56(4):307-14. doi: 10.3109/03008207.2015.1026965. Epub 2015 Apr 29.Xin W, Heilig J, Paulsson M, Zaucke F. Collagen II regulates chondroycte integrin expression profile and differentiation. Connect Tissue Res. 2015;56(4):307-14. doi: 10.3109/03008207.2015.1026965. Epub 2015 Apr 29.Kannu P, Bateman J, Savarirayan R. Clinical phenotypes associated with type II collagen mutations. J Paediatr Child Health. 2012 Feb;48(2):E38-43. doi: 10.1111/j.1440-1754.2010.01979.xKannu P, Bateman J, Savarirayan R. Clinical phenotypes associated with type II collagen mutations. J Paediatr Child Health. 2012 Feb;48(2):E38-43. doi: 10.1111/j.1440-1754.2010.01979.xEyre D. Collagen of articular cartilage. Arthritis Res. 2002;4(1):30-5. Epub 2001 Oct 5. doi:10.1186/ar380Eyre D. Collagen of articular cartilage. Arthritis Res. 2002;4(1):30-5. Epub 2001 Oct 5. doi:10.1186/ar380Prabhoo R, Billa G. Undenatured collagen type II for the treatment of osteoarthritis: a review. Int J Res Orthop. 2018 Sep;4(5): 684-9.Prabhoo R, Billa G. Undenatured collagen type II for the treatment of osteoarthritis: a review. Int J Res Orthop. 2018 Sep;4(5): 684-9.Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi: 10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi: 10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.Rezende RM, Weiner HL. History and mechanisms of oral tolerance. Semin Immunol. 2017 Apr;30:3-11. doi: 10.1016/j.smim.2017.07.004. Epub 2017 Jul 31.Rezende RM, Weiner HL. History and mechanisms of oral tolerance. Semin Immunol. 2017 Apr;30:3-11. doi: 10.1016/j.smim.2017.07.004. Epub 2017 Jul 31.Jaensson E, Uronen-Hansson H, Pabst O, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med. 2008 Sep 1;205(9): 2139-49. doi: 10.1084/jem.20080414. Epub 2008 Aug 18.Jaensson E, Uronen-Hansson H, Pabst O, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med. 2008 Sep 1;205(9): 2139-49. doi: 10.1084/jem.20080414. Epub 2008 Aug 18.Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007 Aug 6; 204(8):1775-85. Epub 2007 Jul 9.Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007 Aug 6; 204(8):1775-85. Epub 2007 Jul 9.Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T-cells. Immunity. 2004 Oct;21(4):527-38. doi: 10.1016/j.immuni.2004.08.011Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T-cells. Immunity. 2004 Oct;21(4):527-38. doi: 10.1016/j.immuni.2004.08.011Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011 May;241(1):241-59. doi: 10.1111/j.1600065X.2011.01017.xWeiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011 May;241(1):241-59. doi: 10.1111/j.1600065X.2011.01017.xKim KS, Hong SW, Han D, et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science. 2016 Feb 19;351(6275):858-63. doi: 10.1126/science.aac5560. Epub 2016 Jan 28.Kim KS, Hong SW, Han D, et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science. 2016 Feb 19;351(6275):858-63. doi: 10.1126/science.aac5560. Epub 2016 Jan 28.Kim KS, Surh CD. Induction of immune tolerance to dietary antigens. Adv Exp Med Biol. 2015;850:93-118. doi: 10.1007/978-3319-15774-0_8Kim KS, Surh CD. Induction of immune tolerance to dietary antigens. Adv Exp Med Biol. 2015;850:93-118. doi: 10.1007/978-3319-15774-0_8Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis Cartilage. 2017 Dec;25(12):2080-90. doi: 10.1016/j.joca.2017.08.013. Epub 2017 Sep 6.Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis Cartilage. 2017 Dec;25(12):2080-90. doi: 10.1016/j.joca.2017.08.013. Epub 2017 Sep 6.Di Cesare Mannelli L, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord. 2013 Aug 1;14:228. doi: 10.1186/1471-2474-14-228Di Cesare Mannelli L, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord. 2013 Aug 1;14:228. doi: 10.1186/1471-2474-14-228Lugo JP, Saiyed ZM, Lau FC, et al. Undenatured type II collagen (UC-II® ) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013 Oct 24;10(1): 48. doi: 10.1186/1550-2783-10-48Lugo JP, Saiyed ZM, Lau FC, et al. Undenatured type II collagen (UC-II® ) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013 Oct 24;10(1): 48. doi: 10.1186/1550-2783-10-48Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi:10.7150/ijms.6.312Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi:10.7150/ijms.6.312Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi: 10.1186/12937-016-0130-8Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi: 10.1186/12937-016-0130-8

The authors declare that there are no conflicts of interest present.